​

Funding Round

Series B - Pionyr Immunotherapeutics

Series B - Pionyr Immunotherapeutics

Investment Firm

Overview

Pionyr Immunotherapeutics is a developer of cancer immunotherapies designed to target the tumor microenvironment.

Announced Date

Dec 13, 2017

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

New Enterprise Associates

New Enterprise Associates

New Enterprise Associates is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.

Sofinnova Investments

Sofinnova Investments

Sofinnova Investments is a early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

10

Investor Name
Participant InvestorSofinnova Investments
Participant InvestorSV Health Investors
Participant InvestorOUP (Osage University Partners)
Participant InvestorJohn Freund
Participant InvestorNew Enterprise Associates

Round Details and Background

Pionyr Immunotherapeutics raised $62000000 on 2017-12-13 in Series B

Pionyr Immunotherapeutics is a developer of cancer immunotherapies designed to target the tumor microenvironment.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 13, 2017
Series B - Pionyr Immunotherapeutics
11-62.0M
Apr 04, 2018
Venture Round - Pionyr Immunotherapeutics
-7.0M
Jun 23, 2020
Corporate Round - Pionyr Immunotherapeutics
1-275.0M
Jan 04, 2017
Series A - Pionyr Immunotherapeutics
5-8.0M

Recent Activity

There is no recent news or activity for this profile.